pp-033 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Solid tumors - specifically a drug targeting the oncogenic pathway via TEAD auto-palmitoylation inhibition. Clinical stage / status: Preclinical development. Oral small-molecule inhibitor of TEAD auto-palmitoylation, designed to overcome ligand-independent activation of TEAD transcription factors in cancer — representing a novel approach to targeting the Hippo/TEAD pathway. Oral small-molecule dosage form
Manufacturer #1228
A leading South Korean pharmaceutical group engaged in developing, manufacturing, and marketing prescription drugs and biologics. It operates GMP-certified facilities, maintains strong R&D capabilities, and exports therapeutic products to global markets.
Manufacturer usually replies in 5 days